A 35-year-old woman with Graves' disease has been on methimazole 15 mg daily for 6 months and is now euthyroid (TSH 1.2 mIU/L, free T4 14 pmol/L). She is planning pregnancy in 3 months. During a routine follow-up, she develops sudden-onset fever (38.5°C), severe pharyngitis, and oral ulcers. Her white blood cell count is 1,800/μL with 5% neutrophils. What is the most appropriate immediate management?

Explanation

## Clinical Scenario Analysis This patient has developed **agranulocytosis** — a life-threatening adverse effect of methimazole characterized by: - Fever, pharyngitis, oral ulcers (infection signs) - WBC 1,800/μL with severe neutropenia (5% neutrophils = ~90 neutrophils/μL) - Onset during methimazole therapy Agranulocytosis is a medical emergency requiring immediate intervention. ## Agranulocytosis: Incidence & Mechanism | Drug | Incidence | Mechanism | Onset | Reversibility | |------|-----------|-----------|-------|---------------| | **Methimazole** | ~0.3–0.5% | Immune-mediated; dose-independent | 1–12 weeks | Yes, if caught early | | **PTU** | ~0.1–0.3% | Immune-mediated; rare | Variable | Yes | | **Iodine** | None | N/A | N/A | N/A | **High-Yield:** Agranulocytosis is **dose-independent** and **idiosyncratic** — it can occur at any dose, even therapeutic ones. It is NOT dose-related toxicity. ## Immediate Management Protocol **Key Point:** The management of antithyroid-induced agranulocytosis follows this hierarchy: 1. **Discontinue the offending drug immediately** (methimazole in this case) 2. **Switch to an alternative antithyroid** (PTU) if thyroid control is still needed 3. **Admit for supportive care**: IV fluids, broad-spectrum antibiotics, isolation 4. **G-CSF (filgrastim)** if neutrophils <500/μL or if sepsis develops 5. **Monitor WBC recovery** — most patients recover within 1–2 weeks if caught early **Clinical Pearl:** PTU is the **alternative of choice** after methimazole agranulocytosis because: - Cross-reactivity is rare (~10% of cases) - Different chemical structure reduces immune cross-recognition - Patient is planning pregnancy (PTU is preferred in pregnancy anyway) ## Why This Answer Is Correct Option B correctly: - **Discontinues methimazole** immediately (life-saving step) - **Switches to PTU** (alternative antithyroid with low cross-reactivity) - **Initiates supportive care** (admission, monitoring) - **Reserves G-CSF** for neutrophils <500/μL or clinical deterioration (appropriate escalation) This is the **evidence-based standard of care** for antithyroid-induced agranulocytosis [cite:KD Tripathi 8e Ch 32]. ## Why Each Distractor Is Wrong **Continuing methimazole (option A):** This is **dangerous and contraindicated**. Continuing the offending drug risks: - Progression to severe sepsis or septic shock - Death from overwhelming infection - Bone marrow aplasia Agranulocytosis is an absolute contraindication to continuing the drug. **Reducing methimazole + iodine (option C):** This is **incorrect and harmful**: - Methimazole must be stopped entirely, not reduced - Iodine is NOT an antithyroid drug for long-term use (escape phenomenon after 10–14 days) - Iodine should NEVER be given before methimazole is stopped (risk of thyroid storm) - This approach leaves the patient without adequate thyroid control and continued agranulocytosis risk **Radioactive iodine (option D):** Radioactive iodine is **contraindicated in acute agranulocytosis** because: - The patient is acutely ill with severe infection - Radioactive iodine causes thyroiditis and hormone release, worsening thyrotoxicosis in the short term - The patient requires immediate thyroid control with PTU, not delayed radioactive iodine therapy - Radioactive iodine is reserved for definitive therapy in stable, euthyroid patients ## Management Algorithm ```mermaid flowchart TD A[Antithyroid Drug Agranulocytosis]:::urgent --> B[Fever + Pharyngitis + WBC <2000]:::urgent B --> C[STOP offending drug immediately]:::action C --> D[Switch to alternative antithyroid]:::action D --> E{Which drug?}:::decision E -->|Methimazole agranulocytosis| F[Start PTU 100 mg TDS]:::action E -->|PTU agranulocytosis| G[Consider Iodine + Beta-blocker]:::action F --> H[Admit for supportive care]:::action H --> I[Broad-spectrum antibiotics]:::action I --> J{Neutrophils <500?}:::decision J -->|Yes| K[G-CSF filgrastim]:::action J -->|No| L[Monitor WBC daily]:::action K --> M[Most recover in 1-2 weeks]:::outcome L --> M ``` ## Key Counseling Points **Warning:** Patients on antithyroid drugs must be counseled to: - Report fever, sore throat, oral ulcers, or unusual infections immediately - NOT self-treat with antibiotics — seek urgent medical evaluation - Understand that agranulocytosis is rare but serious - Know that switching drugs is safe and effective in most cases [cite:KD Tripathi 8e Ch 32; Harrison 21e Ch 405]